Express publication
Cardiac resynchronization therapy: A novel adjunct to the treatment and prevention of systemic right ventricular failure

https://doi.org/10.1016/j.jacc.2004.08.044Get rights and content
Under an Elsevier user license
open archive

Objectives

This study aimed to evaluate the technical feasibility and hemodynamic benefit of cardiac resynchronization therapy (CRT) in patients with systemic right ventricle (RV).

Background

Patients with a systemic RV are at high risk of developing heart failure. Cardiac resynchronization therapy may improve RV function in those with electromechanical dyssynchrony.

Methods

Eight patients (age 6.9 to 29.2 years) with a systemic RV and right bundle-branch block (n = 2) or pacing from the left ventricle (LV) (n = 6) with a QRS intervalof 161 ± 21 ms underwent CRT (associated with cardiac surgery aimed at decrease in tricuspid regurgitation in 3 of 8 patients) and were followed-up for a median of 17.4 months.

Results

Change from baseline rhythm to CRT was accompanied by a decrease in QRS interval (−28.0%, p = 0.002) and interventricular mechanical delay (−16.7%, p = 0.047) and immediate improvement in the RV filling time (+10.9%, p = 0.002), Tei index (−7.7%, p = 0.008), estimated RV maximum +dP/dt(+45.9%, p = 0.007), aortic velocity-time integral (+7.0%, p = 0.028), and RV ejection fraction by radionuclide ventriculography (+9.6%, p = 0.04). The RV fractional area of change increased from a median of 18.1% before resynchronization to 29.5% at last follow-up (p = 0.008) without a significant change in the end-diastolic area (+4.0%, p = NS).

Conclusions

The CRT yielded improvement in systemic RV function in patients with spontaneous or LV pacing-induced electromechanical dyssynchrony and seems to be a promising adjunct to the treatment and prevention of systemic RV failure.

Abbreviations and acronyms

AV
atrioventricular
CRT
cardiac resynchronization therapy
RV
right ventricle/ventricular
LV
left ventricle/ventricular

Cited by (0)

Supported by grant NA/7620-3 of the Internal Grant Agency of the Ministry of Health of the Czech Republic.